TNIB Stock UPDATES Tni Biotech Inc (TNIB) 0.2700 08/20/2014
Post# of 273249
Posted On: 08/20/2014 8:54:30 AM
Tni Biotech Inc (TNIB) 0.2700 $TNIB
TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014
PR Newswire - Mon Aug 18, 9:25AM CDT
TNI BioTech, Inc. (OTC-BB: TNIB) ("we" or the "Company"
a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, announced today that the Company is providing a second notice of TNI BioTech's annual meeting of September 4, 2014.
TNI BioTech, Inc., Announces an Extension to the Record Date of its wholly owned subsidiary, Cytocom Inc., and Dividend now Set for September 30, 2014
PR Newswire - Thu Aug 14, 12:39PM CDT
TNI BioTech, Inc. (OTC-BB: TNIB) ("we" or the "Company" a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, announced today that the Company is extending the record date of the dividend of Cytocom Inc., shares to all shareholders of the Company to September 30th, 2014.
TNI BioTech and Hubei Qianjiang Pharmaceutical Co., Ltd Supplemental Collaborative Agreement
PR Newswire - Wed Aug 13, 7:08AM CDT
TNI BioTech, Inc. (OTC: TNIB) ("TNI" or the "Company" a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, announced today the signing of a supplemental agreement with Hubei Qianjiang Pharmaceutical Co., Ltd (SHSE:600568) ( Qianjiang) China on behalf of Cytocom, TNI BioTech's wholly owed subsidiary. The signing of the supplemental agreement accelerates clinical trial development in both America and China, for IRT-101 ("MENK" . In the hope of moving clinical development forward the parties agreed to the following:
TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card
PR Newswire - Mon Jul 28, 8:00AM CDT
TNI BioTech, Inc. (OTCQB: TNIB) ("TNIB" or the "Company" , a biopharmaceutical company focused on the development, marketing and distribution of opioid-related immunotherapies, announced today that it has filed definitive proxy materials with the Securities and Exchange Commission in connection with its 2014 Annual Meeting of Shareholders to be held on Thursday, September 4, 2014, at 10 a.m., East Standard Time. The record date for determining those shareholders eligible to receive notice of, and to vote at, the 2014 Annual Meeting was set as of July 15, 2014.
TNI BioTech, Inc. Establishes New Record Date for Spin-Off Stock Dividend of Cytocom, Inc. Shares
PR Newswire - Mon Jul 14, 2:17PM CDT
TNI BioTech, Inc. - (OTCQB: TNIB) ("TNIB" or the "Company" , a biotechnology company focused on developing innovative, targeted immune therapies, today announced that its Board of Directors has extended the record date of our spin-off of Cytocom, Inc., a subsidiary of TNIB.
TNI BioTech, Inc. Signs Non-Exclusive Distribution Agreement for Lodonal(TM) for Cancer and Receives First Sale in Africa - CORRECTION
PR Newswire - Wed Jun 25, 10:17AM CDT
TNI BioTech, Inc. (OTC-TNIB) ("TNI BioTech" earlier today announced that its pharmaceutical sales division, Airmed Biopharma Limited, ("Airmed" , a wholly owned Irish Company, has signed a non-exclusive distribution agreement with PanAm Global Logistics, Inc. ("PanAm" to market Lodonal(TM).
TNI BioTech, Inc. Signs Non-Exclusive Distribution Agreement for Lodonal(TM) for Cancer and Receives First Sale in Africa
PR Newswire - Wed Jun 25, 7:35AM CDT
TNI BioTech, Inc. (OTC-TNIB) ("TNI BioTech" is pleased to announce that its pharmaceutical sales division, Airmed Biopharma Limited, ("Airmed" , a wholly owned Irish Company, has signed a non-exclusive distribution agreement with PanAm Global Logistics, Inc. ("PanAm" to market Lodonal(TM).
TNI BioTech, Inc. Cancels Proposed Reverse Split of its Common Stock
PR Newswire - Tue Jun 24, 7:00AM CDT
TNI BioTech, Inc. (OTC: TNIB) ("TNI" or the "Company" a biotechnology company pioneering the development of innovative therapies for autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system, announced today that its Board of Directors had passed a resolution cancelling the previously announced 9:10 reverse split of its common stock, as per the 14A Information Statement filed with the Securities and Exchange Commission on June 18, 2014, and accordingly will notify all appropriate regulatory authorities that the reverse split is withdrawn.
TNI BioTech, Inc. Files Schedule 14A and Announces Annual Meeting
PR Newswire - Wed Jun 18, 7:00AM CDT
TNI BioTech, Inc. (OTC: TNIB) ("TNI" or the "Company" announced today that it will hold its 2014 Annual Meeting ("Annual Meeting" of Stockholders on August 25, 2014. The Company has fixed the close of business on July 11, 2014 as the record date for determining shareholders entitled to notice of, and to vote at, the Annual Meeting. At the Annual Meeting, stockholders will be asked to elect eight directors to serve until the 2015 annual meeting of stockholders and until their successors have been elected and qualified.
TNI BioTech, Inc. Announces Further Agreement on Methionine-Enkephalin with Hubei Qianjiang Pharmaceutical Co., Ltd.
PR Newswire - Wed Mar 26, 9:00AM CDT
TNI BioTech, Inc. (OTC: TNIB), today announced that it has signed a 'Supplementary Cooperation Agreement (the "Agreement" on New Drug Methionine-Enkephalin' with Hubei Qianjiang Pharmaceutical Co., Ltd. (a Chinese listed company, hereinafter referred to as "Qianjiang" .
TNI BioTech, Inc. Granted Additional Patent for Methods for Inducing Sustained Immune Response of T-Cells
PR Newswire - Wed Mar 12, 9:00AM CDT
TNI BioTech, Inc. (OTC: TNIB), a biotech company working to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system using our patented immunotherapy through the acquisition and licensing of late development stage compounds, today announced the U.S. Patent and Trademark Office (USPTO) has granted a key patent for IRT-101 (MENK) for inducing sustained immune response of T-Cells.
The Brewer Group Announces Strategic Partnership with TNI BioTech, Inc.
PR Newswire - Fri Mar 07, 9:00AM CST
The Brewer Group, Inc. ("TBG" a global investment advisory firm, today announced a new strategic partnership with TNI BioTech, Inc. ("TNIB" (OTCQB: TNIB), a biotechnology company pioneering the development of innovative therapies for autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system. Through a variety of business development strategies including exclusive access to its extensive global reach, TBG will provide tailored services including investment banking advisory as well as government, investor relations and marketing support to TNIB in an effort to offer affordable treatment technologies to those in need for as low as $1.00 USD per day in numerous markets throughout the world.
TNI BioTech, Inc. Forms New Subsidiary, Cytocom Inc., to develop LDN and MENK
PR Newswire - Thu Mar 06, 9:00AM CST
TNI BioTech, Inc. (OTC: TNIB) announced today that it has formed a new subsidiary, Cytocom, Inc., for the purpose of developing Low Dose Naltrexone (LDN) and Met-enkephalin (MENK).
TNI BIOTECH Announces SEC Clearance Of Form 10 Registration Statement And Clears Way To Upgrade To A Higher Exchange
PR Newswire - Tue Feb 11, 2:30PM CST
TNI BioTech Inc., (OTCQB:TNIB) a biotechnology company pioneering the development ofinnovative therapies for autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system, today announced that it received notification from the U.S. Securities and Exchange Commission ("SEC" that the SEC has completed its review of the Company's Form 10 registration statement, effectively clearing all comments from the SEC.
TNI BioTech, Inc: Clarification of Press Release Pursuant to Form 8-K
ACCESSWIRE - Fri Sep 13, 11:34AM CDT
BETHESDA, MD, September 13, 2013 - (ACCESSWIRE) - On September 11, 2013 a press release entitled TNI BioTech, Inc. (OTCQB: TNIB) Signs Manufacturing Agreement for IRT-103[TM] LDN and receives $1,500,000 in funding from the exercise of warrants was circulated. It incorrectly stated that the company "received a capital investment of $1,360,625.00 from the conversion existing warrants by our shareholders. The Company believes that other warrant holders will convert and provide the company with additional capital between $250,000 to $500,000 in the coming month." The correct statement, as illustrated by the company's 8-K filed on September 12, 2013 should read:
TNI BioTech, Inc. Signs Manufacturing Agreement for IRT-103[TM] LDN and receives $1,500,000 in funding from the exercise of warrants
Business Wire - Wed Sep 11, 5:00AM CDT
TNI BioTech, Inc. (OTCQB:TNIB) and Laboratorios Ramos announced today that they entered a manufacturing and supply agreement for the production of Low Dose Naltrexone ("LDN" for commercial use. This agreement enables TNIB to focus on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS and autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system. Under the agreement, TNIB and Laboratorios Ramos are responsible for the technology transfer, under a manufacturing agreement, and commercial production of LDN at the Laboratorios Ramos processing facility. Laboratorios Ramos operates "under the principles of the ICH" for cGMP and currently produces commercial products for sale in Nicaragua. The financial terms of the agreement have not been disclosed.
TNI BioTech, Inc. Signs Manufacturing Agreement for IRT-103[TM] LDN
ACCESSWIRE - Wed Sep 04, 7:09AM CDT
BETHESDA, MD, September 4, 2013 - (Accesswire) - TNI BioTech, Inc. (OTCQB: TNIB) and Laboratorios Ramos announced today that they entered a manufacturing and supply agreement for the production of Low Dose Naltrexone ("LDN" for commercial use. This agreement enables TNIB to focus on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS and autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system. Under the agreement, TNIB and Laboratorios Ramos are responsible for the technology transfer, under a manufacturing agreement, and commercial production of LDN at the Laboratorios Ramos processing facility. Laboratorios Ramos operates "under the principles of the ICH" for cGMP and currently produces commercial products for sale in Nicaragua. The financial terms of the agreement have not been disclosed.
TNI BioTech Receives Meeting Minutes from FDA Type C Meeting on Naltrexone HCL for the treatment of Crohn's Disease
ACCESSWIRE - Wed Jul 24, 8:10AM CDT
BETHESDA, MD, July 24, 2013 - (eTeligis via ACCESSWIRE)- TNI BioTech, Inc. (OTCQB: TNIB) is pleased to announce that on July 17, 2013 the company received the official minutes from its recent Type C meeting held June 26, 2013 with the Division of Gastroenterology and Inborn Errors Products regarding the clinical and regulatory aspects of the proposed Phase III development program and future 505(b)(2) application for Low Dose Naltrexone (LDN) in the treatment of adults and pediatric patients with Crohn's Disease. TNI BioTech, Inc. also received official written responses regarding CMC and non-clinical aspects of the LDN development program.
TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014
PR Newswire - Mon Aug 18, 9:25AM CDT
TNI BioTech, Inc. (OTC-BB: TNIB) ("we" or the "Company"
a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, announced today that the Company is providing a second notice of TNI BioTech's annual meeting of September 4, 2014. TNI BioTech, Inc., Announces an Extension to the Record Date of its wholly owned subsidiary, Cytocom Inc., and Dividend now Set for September 30, 2014
PR Newswire - Thu Aug 14, 12:39PM CDT
TNI BioTech, Inc. (OTC-BB: TNIB) ("we" or the "Company"
a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, announced today that the Company is extending the record date of the dividend of Cytocom Inc., shares to all shareholders of the Company to September 30th, 2014. TNI BioTech and Hubei Qianjiang Pharmaceutical Co., Ltd Supplemental Collaborative Agreement
PR Newswire - Wed Aug 13, 7:08AM CDT
TNI BioTech, Inc. (OTC: TNIB) ("TNI" or the "Company"
a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, announced today the signing of a supplemental agreement with Hubei Qianjiang Pharmaceutical Co., Ltd (SHSE:600568) ( Qianjiang) China on behalf of Cytocom, TNI BioTech's wholly owed subsidiary. The signing of the supplemental agreement accelerates clinical trial development in both America and China, for IRT-101 ("MENK" . In the hope of moving clinical development forward the parties agreed to the following: TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card
PR Newswire - Mon Jul 28, 8:00AM CDT
TNI BioTech, Inc. (OTCQB: TNIB) ("TNIB" or the "Company"
, a biopharmaceutical company focused on the development, marketing and distribution of opioid-related immunotherapies, announced today that it has filed definitive proxy materials with the Securities and Exchange Commission in connection with its 2014 Annual Meeting of Shareholders to be held on Thursday, September 4, 2014, at 10 a.m., East Standard Time. The record date for determining those shareholders eligible to receive notice of, and to vote at, the 2014 Annual Meeting was set as of July 15, 2014. TNI BioTech, Inc. Establishes New Record Date for Spin-Off Stock Dividend of Cytocom, Inc. Shares
PR Newswire - Mon Jul 14, 2:17PM CDT
TNI BioTech, Inc. - (OTCQB: TNIB) ("TNIB" or the "Company"
, a biotechnology company focused on developing innovative, targeted immune therapies, today announced that its Board of Directors has extended the record date of our spin-off of Cytocom, Inc., a subsidiary of TNIB. TNI BioTech, Inc. Signs Non-Exclusive Distribution Agreement for Lodonal(TM) for Cancer and Receives First Sale in Africa - CORRECTION
PR Newswire - Wed Jun 25, 10:17AM CDT
TNI BioTech, Inc. (OTC-TNIB) ("TNI BioTech"
earlier today announced that its pharmaceutical sales division, Airmed Biopharma Limited, ("Airmed" , a wholly owned Irish Company, has signed a non-exclusive distribution agreement with PanAm Global Logistics, Inc. ("PanAm" to market Lodonal(TM). TNI BioTech, Inc. Signs Non-Exclusive Distribution Agreement for Lodonal(TM) for Cancer and Receives First Sale in Africa
PR Newswire - Wed Jun 25, 7:35AM CDT
TNI BioTech, Inc. (OTC-TNIB) ("TNI BioTech"
is pleased to announce that its pharmaceutical sales division, Airmed Biopharma Limited, ("Airmed" , a wholly owned Irish Company, has signed a non-exclusive distribution agreement with PanAm Global Logistics, Inc. ("PanAm" to market Lodonal(TM). TNI BioTech, Inc. Cancels Proposed Reverse Split of its Common Stock
PR Newswire - Tue Jun 24, 7:00AM CDT
TNI BioTech, Inc. (OTC: TNIB) ("TNI" or the "Company"
a biotechnology company pioneering the development of innovative therapies for autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system, announced today that its Board of Directors had passed a resolution cancelling the previously announced 9:10 reverse split of its common stock, as per the 14A Information Statement filed with the Securities and Exchange Commission on June 18, 2014, and accordingly will notify all appropriate regulatory authorities that the reverse split is withdrawn. TNI BioTech, Inc. Files Schedule 14A and Announces Annual Meeting
PR Newswire - Wed Jun 18, 7:00AM CDT
TNI BioTech, Inc. (OTC: TNIB) ("TNI" or the "Company"
announced today that it will hold its 2014 Annual Meeting ("Annual Meeting" of Stockholders on August 25, 2014. The Company has fixed the close of business on July 11, 2014 as the record date for determining shareholders entitled to notice of, and to vote at, the Annual Meeting. At the Annual Meeting, stockholders will be asked to elect eight directors to serve until the 2015 annual meeting of stockholders and until their successors have been elected and qualified. TNI BioTech, Inc. Announces Further Agreement on Methionine-Enkephalin with Hubei Qianjiang Pharmaceutical Co., Ltd.
PR Newswire - Wed Mar 26, 9:00AM CDT
TNI BioTech, Inc. (OTC: TNIB), today announced that it has signed a 'Supplementary Cooperation Agreement (the "Agreement"
on New Drug Methionine-Enkephalin' with Hubei Qianjiang Pharmaceutical Co., Ltd. (a Chinese listed company, hereinafter referred to as "Qianjiang" . TNI BioTech, Inc. Granted Additional Patent for Methods for Inducing Sustained Immune Response of T-Cells
PR Newswire - Wed Mar 12, 9:00AM CDT
TNI BioTech, Inc. (OTC: TNIB), a biotech company working to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system using our patented immunotherapy through the acquisition and licensing of late development stage compounds, today announced the U.S. Patent and Trademark Office (USPTO) has granted a key patent for IRT-101 (MENK) for inducing sustained immune response of T-Cells.
The Brewer Group Announces Strategic Partnership with TNI BioTech, Inc.
PR Newswire - Fri Mar 07, 9:00AM CST
The Brewer Group, Inc. ("TBG"
a global investment advisory firm, today announced a new strategic partnership with TNI BioTech, Inc. ("TNIB" (OTCQB: TNIB), a biotechnology company pioneering the development of innovative therapies for autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system. Through a variety of business development strategies including exclusive access to its extensive global reach, TBG will provide tailored services including investment banking advisory as well as government, investor relations and marketing support to TNIB in an effort to offer affordable treatment technologies to those in need for as low as $1.00 USD per day in numerous markets throughout the world. TNI BioTech, Inc. Forms New Subsidiary, Cytocom Inc., to develop LDN and MENK
PR Newswire - Thu Mar 06, 9:00AM CST
TNI BioTech, Inc. (OTC: TNIB) announced today that it has formed a new subsidiary, Cytocom, Inc., for the purpose of developing Low Dose Naltrexone (LDN) and Met-enkephalin (MENK).
TNI BIOTECH Announces SEC Clearance Of Form 10 Registration Statement And Clears Way To Upgrade To A Higher Exchange
PR Newswire - Tue Feb 11, 2:30PM CST
TNI BioTech Inc., (OTCQB:TNIB) a biotechnology company pioneering the development ofinnovative therapies for autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system, today announced that it received notification from the U.S. Securities and Exchange Commission ("SEC"
that the SEC has completed its review of the Company's Form 10 registration statement, effectively clearing all comments from the SEC. TNI BioTech, Inc: Clarification of Press Release Pursuant to Form 8-K
ACCESSWIRE - Fri Sep 13, 11:34AM CDT
BETHESDA, MD, September 13, 2013 - (ACCESSWIRE) - On September 11, 2013 a press release entitled TNI BioTech, Inc. (OTCQB: TNIB) Signs Manufacturing Agreement for IRT-103[TM] LDN and receives $1,500,000 in funding from the exercise of warrants was circulated. It incorrectly stated that the company "received a capital investment of $1,360,625.00 from the conversion existing warrants by our shareholders. The Company believes that other warrant holders will convert and provide the company with additional capital between $250,000 to $500,000 in the coming month." The correct statement, as illustrated by the company's 8-K filed on September 12, 2013 should read:
TNI BioTech, Inc. Signs Manufacturing Agreement for IRT-103[TM] LDN and receives $1,500,000 in funding from the exercise of warrants
Business Wire - Wed Sep 11, 5:00AM CDT
TNI BioTech, Inc. (OTCQB:TNIB) and Laboratorios Ramos announced today that they entered a manufacturing and supply agreement for the production of Low Dose Naltrexone ("LDN"
for commercial use. This agreement enables TNIB to focus on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS and autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system. Under the agreement, TNIB and Laboratorios Ramos are responsible for the technology transfer, under a manufacturing agreement, and commercial production of LDN at the Laboratorios Ramos processing facility. Laboratorios Ramos operates "under the principles of the ICH" for cGMP and currently produces commercial products for sale in Nicaragua. The financial terms of the agreement have not been disclosed. TNI BioTech, Inc. Signs Manufacturing Agreement for IRT-103[TM] LDN
ACCESSWIRE - Wed Sep 04, 7:09AM CDT
BETHESDA, MD, September 4, 2013 - (Accesswire) - TNI BioTech, Inc. (OTCQB: TNIB) and Laboratorios Ramos announced today that they entered a manufacturing and supply agreement for the production of Low Dose Naltrexone ("LDN"
for commercial use. This agreement enables TNIB to focus on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS and autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system. Under the agreement, TNIB and Laboratorios Ramos are responsible for the technology transfer, under a manufacturing agreement, and commercial production of LDN at the Laboratorios Ramos processing facility. Laboratorios Ramos operates "under the principles of the ICH" for cGMP and currently produces commercial products for sale in Nicaragua. The financial terms of the agreement have not been disclosed. TNI BioTech Receives Meeting Minutes from FDA Type C Meeting on Naltrexone HCL for the treatment of Crohn's Disease
ACCESSWIRE - Wed Jul 24, 8:10AM CDT
BETHESDA, MD, July 24, 2013 - (eTeligis via ACCESSWIRE)- TNI BioTech, Inc. (OTCQB: TNIB) is pleased to announce that on July 17, 2013 the company received the official minutes from its recent Type C meeting held June 26, 2013 with the Division of Gastroenterology and Inborn Errors Products regarding the clinical and regulatory aspects of the proposed Phase III development program and future 505(b)(2) application for Low Dose Naltrexone (LDN) in the treatment of adults and pediatric patients with Crohn's Disease. TNI BioTech, Inc. also received official written responses regarding CMC and non-clinical aspects of the LDN development program.
(0)
(0)Scroll down for more posts ▼